Evaluation of individuals with undiagnosed genetic disorders
Official title: Clinical and Genetic Evaluation of Patients With Undiagnosed Disorders Through the Undiagnosed Diseases Network
Run by National Institutes of Health Clinical Center (CC) · NCT02450851 · Data updated 2026-11-12
This study is trying to help people with undiagnosed genetic disorders by using expert evaluations and genetic testing to find answers about their conditions.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Month to 100 Years |
| Sex | All |
| Enrollment | 20000 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 33 sites (Birmingham, Alabama and 32 other locations) |
| Status | Recruiting |
| Started | September 16, 2015 |
| Main results expected | September 16, 2099 |
| Study ends | December 31, 2099 |
| Registry record updated | November 3, 2026 |
| Trial ID | NCT02450851 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with unexplained symptoms and objective findings who have not received a diagnosis despite extensive evaluations by specialists.
✕Probably not a fit
Patients with a known diagnosis that explains their symptoms or those without relevant objective findings are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to provide answers for individuals suffering from undiagnosed genetic diseases by utilizing a collaborative network of experts. Participants undergo comprehensive evaluations, including genetic testing and phenotyping, to identify potential diagnoses and understand disease mechanisms. The study also seeks to generate new knowledge about rare diseases and assess innovative approaches to diagnosis and treatment. By sharing data and biomaterials among research centers, the initiative aims to enhance the understanding of these complex conditions.
Why it matters
Potential benefit: If successful, this study could lead to accurate diagnoses and improved management strategies for patients with previously undiagnosed genetic disorders.
How similar studies have gone: Previous initiatives like the NIH Undiagnosed Diseases Program have successfully identified rare disease diagnoses, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: Ideal participants for tier 2-4 evaluations include individuals with: * One or more objective findings pertinent to the phenotype for which a case was submitted. * No diagnosis despite evaluation by specialists who assessed the patient for the objective finding(s). * Agreement for the storage and sharing of information and biomaterials, in an identified fashion amongst the UDN centers, and in a de-identified fashion to research sites beyond the network. Participants unable to consent can be enrolled. EXCLUSION CRITERIA: Individuals who are unlikely to be assigned to tier 2-4 evaluations include those with: * Reported symptoms with no relevant objective findings. * A diagnosis explaining objective findings. * A diagnosis suggested on record review. * Unwillingness to share data.
Where it's running
-
University of Alabama at Birmingham
Birmingham, Alabama, United States Recruiting -
University of California, Los Angeles
Los Angeles, California, United States Recruiting -
University of California, Irvine Medical Center
Orange, California, United States Recruiting -
Stanford University
Stanford, California, United States Recruiting -
Leland Stanford Junior University
Stanford, California, United States Recruiting -
Stanford Hospital and Clinics
Stanford, California, United States Recruiting
Show 27 more locations
-
Childrens National Medical Center
Washington D.C., District of Columbia, United States Recruiting -
University of Miami Miller School of Medicine
Miami, Florida, United States Recruiting -
Indiana University
Indianapolis, Indiana, United States Recruiting -
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting -
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting -
Boston Children s Hospital
Boston, Massachusetts, United States Recruiting -
Brigham and Women's Hospital
Boston, Massachusetts, United States Recruiting -
Mayo Clinic
Rochester, Minnesota, United States Recruiting -
Washington University in St. Louis
St Louis, Missouri, United States Recruiting -
Duke University Health System
Durham, North Carolina, United States Recruiting -
University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting -
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States Recruiting -
Vanderbilt University Medical Center
Nashville, Tennessee, United States Recruiting -
Baylor College of Medicine
Houston, Texas, United States Recruiting -
University of Utah
Salt Lake City, Utah, United States Recruiting -
Seattle Children's Hospital
Seattle, Washington, United States Recruiting -
University of Washington
Seattle, Washington, United States Recruiting -
Medical College of Wisconsin
Milwaukee, Wisconsin, United States Recruiting -
HudsonAlpha Institute for Biotechnology, Inc.
Huntsville, Alabama, United States Completed -
Lucile Salter Packard Children's Hospital at Stanford
Stanford, California, United States Completed -
Lurie Children s Hospital
Chicago, Illinois, United States Not yet recruiting -
Harvard T.H. Chan School of Public Health
Boston, Massachusetts, United States Completed -
Harvard U Faculty of Medicine
Boston, Massachusetts, United States Not yet recruiting -
New York Genome Center
New York, New York, United States Active not recruiting -
University of Oregon
Eugene, Oregon, United States Not yet recruiting -
Oregon Health Sciences University
Portland, Oregon, United States Completed -
Pacific Northwest National Laboratory
Richland, Washington, United States Completed
Study contacts
- Principal investigator: William A Gahl, M.D. — National Human Genome Research Institute (NHGRI)
- Study coordinator: Paul Mazur
- Email: udn@hms.harvard.edu
- Phone: (844) 746-4836
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Newborn whole-genome sequencing and genetic disease risk in pregnancy and early life
This project will collect small biological samples from pregnant families and newborns to try whole-genome sequencing and other multi-omics tests to find genetic disease risks.
-
Multicenter study of SHANK3-related Phelan-McDermid syndrome genetic modifiers
Researchers are testing how other genes may modify the PMS clinical picture in people with SHANK3-related deletions or variants.
-
Prenatal cfDNA Screening in Pregnancies with Diverse Genetic Risk Profiles
This study tests two cfDNA approaches from a single maternal blood sample to see if they can detect a wide range of fetal genetic conditions in pregnant people with various risk factors.
-
Natural history of type I interferonopathies in a European patient group
This project will follow people with genetically confirmed type I interferonopathies across European centers to see how the disease develops and which clinical and blood markers track disease activity.
-
Speech-generating device to help communication in childhood dementia
This project will test whether giving children with childhood dementia a speech-generating iPad app helps them communicate better than their usual care.
-
Using AI to enhance cardiology patient care
This study is testing if using AI tools can help cardiologists make better decisions when treating patients with heart conditions compared to traditional methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.